FDA Clears Opus Genetics’ Eye Drop for Presbyopia
The approval expands RYZUMVI’s use to adults with presbyopia and triggers a milestone payment to Opus Genetics.
Makkler Newsroom · Oct 16, 07:24 PM · 1 min read
Market open· · AUD · Data may be delayed
Not enough data
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.